Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing
On September 12, 2022, Aprea Therapeutics, Inc. (the "Company") received a
deficiency letter from the Listing Qualifications Department (the "Staff") of
the Nasdaq Stock Market ("Nasdaq") notifying the Company that, for the preceding
30 consecutive business days, the closing bid price for the Company's common
stock was below the minimum $1.00 per share requirement for continued inclusion
on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1)
(the "Bid Price Requirement"). The notification received has no immediate effect
on the Company's Nasdaq listing and the Company's common stock will continue to
trade on Nasdaq under the symbol "APRE" at this time. In accordance with Nasdaq
rules, the Company has been provided an initial period of 180 calendar days, or
until March 13, 2023 (the "Compliance Date"), to regain compliance with the Bid
Price Requirement. If, at any time before the Compliance Date, the closing bid
price for the Company's common stock is at least $1.00 for a minimum of 10
consecutive business days, the Staff will provide the Company written
confirmation of compliance with the Bid Price Requirement. If the Company does
not regain compliance with the Bid Price Requirement by the Compliance Date, the
Company may be eligible for an additional 180 calendar day compliance period. To
qualify, the Company will be required to transfer to the Nasdaq Capital Market
and to meet the continued listing requirement for market value of publicly held
shares and all other initial listing standards for the Nasdaq Capital Market,
with the exception of the Bid Price Requirement, and will need to provide
written notice of its intention to cure the deficiency during the additional 180
calendar day compliance period, by effecting a reverse stock split, if
necessary. If the Company does not regain compliance with the Bid Price
Requirement by the Compliance Date and is not eligible for an additional
compliance period at that time, the Staff will provide written notification to
the Company that its common stock will be subject to delisting. At that time,
the Company may appeal the Staff's delisting determination to a Nasdaq Hearings
Panel. There can be no assurance that the Company will regain compliance or
otherwise maintain compliance with any of the other listing requirements. The
Company intends to monitor the closing bid price of its common stock and may, if
appropriate, consider available options to regain compliance with the Bid Price
Requirement.
© Edgar Online, source Glimpses